Wealthcare Advisory Partners’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Wealthcare Advisory Partners’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,600	Closed	-$39K	–	1235
2018 Q2	$39K	Hold	1,600	–	–	0.01%	512
2018 Q1	$46K	Hold	1,600	–	–	0.01%	410
2017 Q4	$38K	Hold	1,600	–	–	0.01%	419
2017 Q3	$43K	Buy	+1,600	New	+$38.9K	0.01%	323

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CIA

Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return

Wealthcare Advisory Partners's CNCR Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2018, closing a stake of 1,600 shares — an estimated $39K sold.

Wealthcare Advisory Partners first reported a position in CNCR in Q3 2017 and held it in 4 quarters. The position peaked at $46K in Q1 2018. 23 funds tracked by Wall St. Rank hold CNCR as of Q3 2018.

Wealthcare Advisory Partners reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2018 after selling out during the quarter.
Wealthcare Advisory Partners sold 1,600 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2018, an estimated $39K.
Wealthcare Advisory Partners first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2017 and held it in 4 quarters.
Wealthcare Advisory Partners's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $46K in Q1 2018.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.